EAST HANOVER, N.J., Dec. 10, 2024 -- Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali ® (ribociclib) that underscore the extended efficacy ...
Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancer Montreal, Quebec, December 13, 2024 – ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies, providing quality generics and biosimilars, and finding new ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From ...
诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback